Blood Tests to Predict Preterm Birth Early

Preterm birth, defined as delivery before 37 weeks of gestation, affects millions globally and remains the top cause of neonatal mortality. Recent advancements in blood-based diagnostics are changing this landscape by identifying at-risk pregnancies early, allowing for proactive care.

The Global Challenge of Premature Deliveries

Every year, over 10% of births worldwide occur prematurely, leading to immediate health risks like respiratory distress and long-term issues such as developmental delays. In the U.S., prematurity impacts about 9-11% of pregnancies, contributing significantly to infant deaths under age 5. Traditional risk factors—such as prior preterm birth, infections, or multiple gestations—help somewhat, but they miss many cases. Clinicians often lack reliable tools to forecast spontaneous preterm labor accurately.

Without prediction, interventions come too late. This gap has driven researchers to explore maternal blood for subtle signals from the fetus, placenta, and mother’s body, revealing pregnancy dynamics non-invasively.

How Blood Tests Detect Preterm Risks

Modern tests analyze cell-free components in maternal plasma: RNA transcripts or DNA fragments shed by the placenta and fetus. These biomarkers reflect physiological changes signaling instability.

Key mechanisms include:

• Cell-free RNA (cfRNA) profiling: Measures gene activity from maternal, fetal, and placental sources. Specific gene sets predict delivery timing with 75-80% accuracy.
• Cell-free DNA (cfDNA) promoter analysis: Examines nucleosome positioning around gene promoters via whole-genome sequencing, correlating with tissue expression and preterm signals.
• Immune function biomarkers: Detects alterations from chronic stress, linking to inflammation and labor triggers.

These approaches use routine blood draws, often from standard prenatal screens, minimizing added burden.

Pioneering Research from Leading Institutions

Stanford University’s team pioneered cfRNA testing in 2018, sequencing plasma to track gene expression. They identified markers distinguishing preterm from term pregnancies, also estimating gestational age as reliably as ultrasound—crucial in resource-limited areas. Validation in larger cohorts is underway to refine clinical use.

More recently, a 2025 PLOS Medicine study from Chinese researchers used cfDNA from weeks 12-28. Their PTerm classifier, based on promoter coverage depth, achieved an AUC of 0.85 across validation sets, highlighting genes like ERBB2 and ESR1 as preterm indicators.

Ohio State University researchers, led by Shannon Gillespie, developed an immune-focused test measuring stress-induced changes. Preliminary data show up to 97.5% accuracy using minimal blood volume, integrable into routine prenatal panels.

Accuracy, Limitations, and Validation Progress

Reported accuracies vary: Stanford’s 75-80% for preterm risk, PTerm’s high discrimination in case-controls, and Ohio State’s promising prelims. These outperform many historical models but require prospective trials for real-world validation.

Challenges include:

• Ethnic diversity: Most data from specific populations; broader testing needed.
• False positives: Could lead to unnecessary interventions.
• Cost and access: Though simple, scaling in low-resource settings is key.

Ongoing studies aim to combine biomarkers for better precision and explore causal pathways for treatments.

Clinical Applications and Early Interventions

Positive tests prompt tailored strategies:

• Progesterone therapy: Weekly injections reduce recurrence risk by 30-40% in high-risk cases.
• Cervical cerclage: Stitching for short cervix, preventing ascent.
• Lifestyle modifications: Bed rest, stress reduction, smoking cessation.
• Antenatal steroids: Lung maturation if delivery seems imminent.

Integrating tests into ‘prenatal batteries’ could stratify risks early, personalizing care and averting crises.

Real-World Impact and Patient Stories

For families like Ebony’s—whose first child was lost preterm but second survived after interventions—these tools offer hope. Early detection enabled monitoring and preventives, turning tragedy to triumph.

Globally, accurate gestational dating aids nutrition and vaccination timing, vital in developing regions.

Future Directions in Predictive Prenatal Testing

Researchers envision multi-omics panels merging RNA, DNA, and proteins for near-perfect forecasts. Drug discovery targeting prematurity genes could prevent onset. AI integration may enhance model robustness across demographics.

Regulatory hurdles loom, but FDA pathways for companion diagnostics are opening. Commercial tests may soon join NIPT panels.

Frequently Asked Questions

Can any pregnant woman get a preterm blood test?

Currently experimental; available in trials or select clinics. Routine use awaits full validation.

How accurate are these tests?

75-97.5% in studies, but varies by method and population. Not infallible—combine with clinical judgment.

Does the test harm the baby?

No; noninvasive, using maternal blood only.

What if the test predicts preterm birth?

Triggers monitoring, meds like progesterone, or lifestyle changes to mitigate risks.

When will these tests be widely available?

Prospective trials ongoing; clinical integration possible in 2-5 years.

Empowering Pregnancies Through Science

These blood tests mark a shift from reactive to preventive obstetrics, potentially slashing preterm rates and associated costs—estimated at billions annually. By decoding pregnancy’s molecular whispers, we edge closer to full-term health for all.